Silvia Novello

Research interests

Publications

• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

  Journal of Clinical Oncology · 2023 · 10.1200/jco.22.01990

• Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2302983

• Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.11.025

• Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.03136

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30634-5

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz167

• Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.07.025

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30634-5

• Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

  Annals of Oncology · 2018 · 10.1093/annonc/mdy405

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy275

• Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy121

• Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1801005

• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810865

• Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.70.3223

• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30339-x

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw326

• Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30146-2

• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(13)70586-2

• 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu123

• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu145

• 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu089

• Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.1321

• Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

  Journal of Endocrinological Investigation · 2006 · https://doi.org/10.1007/bf03344099

• Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

  Cancer · 2006 · https://doi.org/10.1002/cncr.22208

• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

  Annals of Oncology · 2006 · https://doi.org/10.1093/annonc/mdl300

• Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.02.527

• Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial

  JNCI Journal of the National Cancer Institute · 2003 · 10.1093/jnci/95.5.362

Current projects

No projects listed.